Article
Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma.
Human pathology - 1 Aug 2015
Tetzlaff Michael T, Pattanaprichakul Penvadee, Wargo Jennifer, Fox Patricia S, Patel Keyur P, Estrella Jeannelyn S, Broaddus Russell R, Williams Michelle D, Davies Michael A, Routbort Mark J, Lazar Alexander J, Woodman Scott E, Hwu Wen-Jen, Gershenwald Jeffrey E, Prieto Victor G, Torres-Cabala Carlos A, Curry Jonathan L
Abstract excerpt
Successful BRAF inhibitor therapy depends on the accurate assessment of the mutation status of the BRAF V600 residue in tissue samples. In melanoma, immunohistochemical (IHC) analysis with monoclonal anti-BRAF V600E has emerged as a sensitive and specific surrogate of BRAF V600E mutation, particularly when BRAF V600E protein expression is homogeneous and strong. A subset of melanomas exhibit heterogeneous...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
